Expertise in
20
conditions

Dr. Amandeep Salhotra

Oncology
Amandeep Salhotra, M.D.
1500 Duarte Rd, 
Duarte, CA 
Offers Telehealth
21 Years of Experience
Expertise in
20
conditions
Amandeep Salhotra, M.D.
1500 Duarte Rd, 
Duarte, CA 

Overview

Amandeep Salhotra is an Oncologist practicing medicine in Duarte, California. He has been practicing medicine for over 21 years.

Dr. Salhotra is highly rated in 20 conditions, according to our data. His clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Bone Marrow Aspiration, and Colonoscopy.

He is actively involved in clinical research, co-authoring 127 peer reviewed articles and participating in 12 clinical trials.

Specialties

Oncology

Licenses

Internal Medicine in MA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
HMSA
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Inland Empire Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

Amandeep Salhotra, M.D.
1500 Duarte Rd, Duarte, CA 91010

Additional Areas of Focus

Dr. Salhotra has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Adult Immune Thrombocytopenia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

Phase 2 Trial of Enasidenib (AG-221) Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients With IDH2 Mutation
Phase 2 Trial of Enasidenib (AG-221) Maintenance Post Allogeneic Hematopoietic Cell Transplantation in Patients With IDH2 Mutation
Enrollment Status: Suspended
Publish Date: August 21, 2026
Intervention Type: Drug
Study Drug: Enasidenib Mesylate
Study Phase: Phase 2
A Safety and Feasibility Trial of Leflunomide in Patients With Steroid Dependent Chronic Graft-Versus-Host Disease
A Safety and Feasibility Trial of Leflunomide in Patients With Steroid Dependent Chronic Graft-Versus-Host Disease
Enrollment Status: Active_not_recruiting
Publish Date: July 08, 2026
Intervention Type: Drug
Study Drug: Leflunomide
Study Phase: Phase 1
A Phase 1 Study of M3814 in Combination With MEC in Patients With Relapsed or Refractory Acute Myeloid Leukemia
A Phase 1 Study of M3814 in Combination With MEC in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Drug, Procedure
Study Drugs: Cytarabine, Etoposide Phosphate, Mitoxantrone Hydrochloride, Peposertib
Study Phase: Phase 1
A Phase 1B Study of KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Acute Myeloid Leukemia
A Phase 1B Study of KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: June 11, 2026
Intervention Type: Procedure, Drug
Study Drugs: Decitabine, KRT-232
Study Phase: Phase 1
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Randomized Phase II Study to Assess the Role of Nivolumab as Single Agent to Eliminate Minimal Residual Disease and Maintain Remission in Acute Myelogenous Leukemia (AML) Patients After Chemotherapy (REMAIN TRIAL)
Enrollment Status: Active_not_recruiting
Publish Date: May 28, 2026
Intervention Type: Procedure, Biological, Other
Study Drug: Nivolumab
Study Phase: Phase 2
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: November 10, 2025
Intervention Type: Drug, Biological
Study Drugs: Ixazomib, Lenalidomide, Dexamethasone
Study Phase: Phase 2
Phase II Trial of Extracorporeal Photopheresis (ECP) Plus Low Dose IL-2 for Treatment of Steroid Refractory Chronic Graft-versus-Host Disease (cGVHD)
Phase II Trial of Extracorporeal Photopheresis (ECP) Plus Low Dose IL-2 for Treatment of Steroid Refractory Chronic Graft-versus-Host Disease (cGVHD)
Enrollment Status: Completed
Publish Date: April 08, 2024
Intervention Type: Other, Biological, Procedure
Study Drug: Aldesleukin
Study Phase: Phase 2
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
A Phase 1 / 2 Study to Evaluate the Safety, Tolerability and Initial Anti-Tumor Activity of Adoptively Transferred T Lymphocytes Targeting WT1, PRAME and Cyclin A1 AML or MDS Patients With Relapsed Disease After Matched Allogeneic HCT
Enrollment Status: Unknown
Publish Date: January 16, 2024
Intervention Type: Biological
Study Drug: NEXI-001 T Cell Infusion
Study Phase: Phase 1/Phase 2
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
A Phase IIa Study of BL-8040 in Combination With Nelarabine for Relapsed or Refractory T-Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma
Enrollment Status: Terminated
Publish Date: October 31, 2023
Intervention Type: Drug
Study Drugs: BL-8040 CD34-Positive Hematopoietic Cells, Nelarabine
Study Phase: Phase 2
An Open-label Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute Graft Versus Host Disease (aGVHD)
An Open-label Study of ALPN-101 in Steroid-resistant or Steroid-refractory Acute Graft Versus Host Disease (aGVHD)
Enrollment Status: Terminated
Publish Date: August 28, 2023
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

127 Total Publications

Pediatric-inspired therapy and blinatumomab consolidation improve outcomes in young adults with Philadelphia-like acute lymphoblastic leukemia.
Pediatric-inspired therapy and blinatumomab consolidation improve outcomes in young adults with Philadelphia-like acute lymphoblastic leukemia.
Journal: Haematologica
Published: June 24, 2026
Similar Doctors
Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required

City Of Hope - Duarte Main Campus

1500 E Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
626-256-4673
Experience:
17+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alex Herrera is an Oncologist practicing medicine in Duarte, CA. He has been practicing medicine for over 17 years. Dr. Herrera is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Colonoscopy. Dr. Herrera is board certified in American Board Of Internal Medicine, Hematology and American Board Of Internal Medicine, Oncology.

Expertise in
26
conditions
Expertise in
26
conditions
Referral may be required

City Of Hope Comprehensive Cancer Center-Duarte

1500 Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
888-304-3959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sumanta Pal is an Oncologist practicing medicine in Duarte, California. Dr. Pal is highly rated in 26 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

City Of Hope Comprehensive Cancer Center-Duarte

1500 Duarte Rd, 
Duarte, CA 
 (0.1 miles away)
626-275-8064
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hope Rugo is an Oncologist practicing medicine in Duarte, California. Dr. Rugo is highly rated in 18 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Triple-Negative Breast Cancer, PIK3CA-Related Overgrowth Spectrum, Bone Marrow Aspiration, and Vertebroplasty.

Frequently Asked Questions about Dr. Amandeep Salhotra

How do I make an appointment with Dr. Amandeep Salhotra?

You can book an appointment with Dr. Amandeep Salhotra by calling their office at 800-826-4673. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Amandeep Salhotra a top-rated expert for Chronic Graft Versus Host Disease (cGvHD)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Amandeep Salhotra is classified as an Elite expert for Chronic Graft Versus Host Disease (cGvHD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Amandeep Salhotra specialize in?

While Dr. Amandeep Salhotra is a Oncology, they have specific expertise in Chronic Graft Versus Host Disease (cGvHD), Acute Myeloid Leukemia (AML), and Acute Lymphoblastic Leukemia (ALL). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Amandeep Salhotra participate in research or clinical trials?

Yes. Dr. Amandeep Salhotra has published 127 articles and abstracts on conditions like Chronic Graft Versus Host Disease (cGvHD). You can view a list of Dr. Amandeep Salhotra's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Amandeep Salhotra accept my insurance?

Dr. Amandeep Salhotra accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 800-826-4673 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Salhotra's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 28 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile